Surgery for recurrent ovarian cancer

Women's Health

Volumn 7, Issue 5, 2011, Pages 529-535

  Heitz, Florian ^a   Du Bois, Andreas ^a   Kurzeder, Christian ^a   Pfisterer, Jacobus ^b   Barinoff, Jana ^a   Grabowski, Jacek ^a   Hilpert, Felix ^c   Mahner, Sven ^d   Harter, Philipp ^a  

^a KLINIKEN ESSEN MITTE   (Germany)

^b STÄDTISCHES KLINIKUM SOLINGEN   (Germany)

^c UNIVERSITY HOSPITAL SCHLESWIG HOLSTEIN   (Germany)

^d UNIVERSITY MEDICAL CENTER HAMBURG EPPENDORF   (Germany)

Author keywords

AGO DESKTOP; ovarian cancer; platinum sensitive ovarian cancer; recurrent ovarian cancer; secondary cytoreductive surgery; surgery

Indexed keywords

CA 125 ANTIGEN;

ADVANCED CANCER; ANTIGEN DETECTION; CANCER PALLIATIVE THERAPY; CANCER SURGERY; CARCINOMATOUS PERITONITIS; CYTOREDUCTIVE SURGERY; DISEASE FREE SURVIVAL; HUMAN; MORBIDITY; OUTCOME ASSESSMENT; OVARY CANCER; PATIENT CARE; PROGNOSIS; RECURRENT CANCER; REVIEW; RISK ASSESSMENT; SURGICAL MORTALITY; TREATMENT INDICATION;

ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC AGENTS, PHYTOGENIC; CARBOPLATIN; FEMALE; GYNECOLOGIC SURGICAL PROCEDURES; HUMANS; MEDICAL ONCOLOGY; NEOPLASM RECURRENCE, LOCAL; OVARIAN NEOPLASMS; PACLITAXEL; PROGNOSIS; SURVIVAL ANALYSIS; TREATMENT OUTCOME;

EID: 80052490915     PISSN: 17455057     EISSN: 17455065     Source Type: Journal    
DOI: 10.2217/whe.11.52     Document Type: Review

References (43)

1. Heintz AP, Odicino F, Maisonneuve P et al. Carcinoma of the ovary. FIGO 26th Annual Report on the Results of Treatment in Gynecological Cancer. Int. J. Gynaecol. Obstet. 95(Suppl. 1), S161-S192 (2006).
2. Jemal A, Siegel R, Xu J, Ward E. Cancer statistics. CA Cancer J. Clin. 60(5), 277-300 (2010).
3. du Bois A, Luck HJ, Meier W et al. A randomized clinical trial of cisplatin/ paclitaxel versus carboplatin/paclitaxel as first-line treatment of ovarian cancer. J. Nat. Cancer. Int. 95(17), 1320-1329 (2003).
4. Stuart GC, Kitchener H, Bacon M et al. Gynecologic Cancer InterGroup (GCIG) consensus statement on clinical trials in ovarian cancer: report from the Fourth Ovarian Cancer Consensus Conference. Int. J. Gynecol. Cancer 21(4), 750-755 (2010).
5. Pujade-Lauraine E, Wagner U, Aavall-Lundqvist E et al. Pegylated liposomal Doxorubicin and Carboplatin compared with Paclitaxel and Carboplatin for patients with platinum-sensitive ovarian cancer in late relapse. J. Clin. Oncol. 28(20), 3323-3329 (2010).
6. Parmar MK, Ledermann JA, Colombo N et al. Paclitaxel plus platinum-based chemotherapy versus conventional platinum-based chemotherapy in women with relapsed ovarian cancer: the ICON4/AGO-OVAR-22 trial. Lancet, 361(9375), 2099-2106 (2003).
7. Pfisterer J, Plante M, Vergote I et al. Gemcitabine plus carboplatin compared with carboplatin in patients with platinum-sensitive recurrent ovarian cancer: an intergroup trial of the AGO-OVAR, the NCIC CTG, and the EORTC GCG. J. Clin. Oncol. 24(29), 4699-4707 (2006). (Pubitemid 46630933)
8. Gordon AN, Fleagle JT, Guthrie D, Parkin DE, Gore ME, Lacave AJ. Recurrent epithelial ovarian carcinoma: a randomized phase III study of pegylated liposomal doxorubicin versus topotecan. J. Clin. Oncol. 19(14), 3312-3322 (2001). (Pubitemid 32642183)
9. Meier W, du Bois A, Reuss A et al. Topotecan versus treosulfan, an alkylating agent, in patients with epithelial ovarian cancer and relapse within 12 months following 1st-line platinum/paclitaxel chemotherapy. A prospectively randomized phase III trial by the Arbeitsgemeinschaft Gynaekologische Onkologie Ovarian Cancer Study Group (AGO-OVAR).Gynecol. Oncol. 114(2), 199-205 (2009).
10. Sehouli J, Stengel D, Harter P et al. Topotecan Weekly Versus Conventional 5-Day Schedule in Patients With Platinum- Resistant Ovarian Cancer: a randomized multicenter phase II trial of the North- Eastern German Society of Gynecological Oncology Ovarian Cancer Study Group. J. Clin. Oncol. 29(2), 242-248 (2011).
11. Ferrandina G, Ludovisi M, Lorusso D et al. Phase III trial of gemcitabine compared with pegylated liposomal doxorubicin in progressive or recurrent ovarian cancer. J. Clin. Oncol. 26(6), 890-896 (2008). (Pubitemid 351398081)
12. Mutch DG, Orlando M, Goss T et al. Randomized phase III trial of gemcitabine compared with pegylated liposomal doxorubicin in patients with platinum-resistant ovarian cancer. J. Clin. Oncol. 25(19), 2811-2818 (2007).
13. du Bois A, Quinn M, Thigpen T et al. 2004 consensus statements on the management of ovarian cancer: final document of the 3rd International Gynecologic Cancer Intergroup Ovarian Cancer Consensus Conference (GCIG OCCC 2004).Ann. Oncol. 16(Suppl. 8), viii7-viii12 (2005). (Pubitemid 41631227)
14. Sharp F, Blackett AD, Leake RE, Berek JS. Conclusions and recommendations from the Helene Harris Memorial Trust Fifth Biennial International Forum on Ovarian Cancer, May 4-7, 1995, Glasgow, UK. Int. J. Gynecol. Cancer 5(6), 449-458 (1995).
15. Berek JS, Trope C, Vergote I. Surgery during chemotherapy and at relapse of ovarian cancer. Ann. Oncol. 10(Suppl. 1), 3-7 (1999).
16. McGuire WP, Hoskins WJ, Brady MF et al. Cyclophosphamide and cisplatin compared with paclitaxel and cisplatin in patients with stage III and stage IV ovarian cancer. N. Engl. J. Med. 334(1), 1-6 (1996). (Pubitemid 26012496)
17. Ozols RF, Bundy BN, Greer BE et al. Phase III trial of carboplatin and paclitaxel compared with cisplatin and paclitaxel in patients with optimally resected stage III ovarian cancer: a Gynecologic Oncology Group study. J. Clin. Oncol. 21(17), 3194-3200 (2003). (Pubitemid 46606249)
18. Piccart MJ, Bertelsen K, James K et al. Randomized intergroup trial of cisplatin-paclitaxel versus cisplatin-cyclophosphamide in women with advanced epithelial ovarian cancer: three-year results. J. Nat. Cancer Int. 92(9), 699-708 (2000). (Pubitemid 30365530)
19. du Bois A, Herrstedt J, Hardy-Bessard AC et al. Phase III trial of carboplatin plus paclitaxel with or without gemcitabine in first-line treatment of epithelial ovarian cancer. J. Clin. Oncol. 28(27), 4162-4169 (2010).
20. Winter WE, 3rd, Maxwell GL, Tian C et al. Prognostic factors for stage III epithelial ovarian cancer: a Gynecologic Oncology Group Study. J. Clin. Oncol. 25(24), 3621-3627 (2007). (Pubitemid 47372600)
21. du Bois A, Reuss A, Pujade-Lauraine E, Harter P, Ray-Coquard I, Pfisterer J. Role of surgical outcome as prognostic factor in advanced epithelial ovarian cancer: a combined exploratory analysis of 3 prospectively randomized Phase 3 multicenter trials: by the Arbeitsgemeinschaft Gynaekologische Onkologie Studiengruppe Ovarialkarzinom (AGO-OVAR) and the Groupe d'Investigateurs Nationaux Pour les Etudes des Cancers de l'Ovaire (GINECO).Cancer 115(6), 1234-1244 (2009).
22. Winter WE 3rd, Maxwell GL, Tian C et al. Tumor residual after surgical cytoreduction in prediction of clinical outcome in stage IV epithelial ovarian cancer: a Gynecologic Oncology Group Study. J. Clin. Oncol. 26(1), 83-89 (2008).
23. Harter P, du Bois A. The role of surgery in ovarian cancer with special emphasis on cytoreductive surgery for recurrence. Curr. Opin. Oncol. 17(5), 505-514 (2005). (Pubitemid 41224935)
24. Bristow RE, Puri I, Chi DS. Cytoreductive surgery for recurrent ovarian cancer: a metanalysis. Gynecol. Oncol. 112(1), 265-274 (2009).
25. Eisenkop SM, Friedman RL, Spirtos NM. The role of secondary cytoreductive surgery in the treatment of patients with recurrent epithelial ovarian carcinoma. Cancer 88(1), 144-153 (2000). (Pubitemid 30027690)
26. Sehouli J, Richter R, Braicu EI et al. Role of secondary cytoreductive surgery in ovarian cancer relapse: who will benefit? A systematic analysis of 240 consecutive patients. J. Surg. Oncol. 102(6), 656-662 (2010).
27. Scarabelli C, Gallo A, Carbone A. Secondary cytoreductive surgery for patients with recurrent epithelial ovarian carcinoma. Gynecol. Oncol. 83(3), 504-512 (2001). (Pubitemid 33139711)
28. Zang RY, Zhang ZY, Li ZT et al. Effect of cytoreductive surgery on survival of patients with recurrent epithelial ovarian cancer. J. Surg. Oncol. 75(1), 24-30 (2000).
29. Chi DS, McCaughty K, Diaz JP et al. Guidelines and selection criteria for secondary cytoreductive surgery in patients with recurrent, platinum-sensitive epithelial ovarian carcinoma. Cancer 106(9), 1933-1939 (2006). (Pubitemid 43673208)
30. Fleming ND, Cass I, Walsh CS, Karlan BY, Li AJ. CA125 surveillance increases optimal resectability at secondary cytoreductive surgery for recurrent epithelial ovarian cancer. Gynecol. Oncol. 121(2), 249-252 (2011).
31. Gronlund B, Lundvall L, Christensen IJ, Knudsen JB, Hogdall C. Surgical cytoreduction in recurrent ovarian carcinoma in patients with complete response to paclitaxel-platinum. Eur. J. Surg. Oncol. 31(1), 67-73 (2005). (Pubitemid 40103927)
32. Zang RY, Zhang ZY, Li ZT et al. Impact of secondary cytoreductive surgery on survival of patients with advanced epithelial ovarian cancer. Eur. J. Surg. Oncol. 26(8), 798-804 (2000).
33. Harter P, du Bois A, Hahmann M et al. Surgery in recurrent ovarian cancer: the Arbeitsgemeinschaft Gynaekologische Onkologie (AGO) DESKTOP OVAR trial. Ann. Surg. Oncol. 13(12), 1702-1710 (2006). (Pubitemid 44951480)
34. Harter P, Hahmann M, Lueck HJ et al. Surgery for recurrent ovarian cancer: role of peritoneal carcinomatosis: exploratory analysis of the DESKTOP I trial about risk factors, surgical implications, and prognostic value of peritoneal carcinomatosis. Ann. Surg. Oncol. 16(5), 1324-1330 (2009).
35. Harter P, Sehouli J, Reuss A et al. Prospective validation study of a predictive score for operability of recurrent ovarian cancer: the Multicenter Intergroup Study DESKTOP II. A project of the AGO Kommission OVAR, AGO Study Group, NOGGO, AGOustria, and MITO. Int. J. Gynecol. Cancer 21(2), 289-295 (2011).
36. Helm CW, Randall-Whitis L, Martin RS 3rd et al. Hyperthermic intraperitoneal chemotherapy in conjunction with surgery for the treatment of recurrent ovarian carcinoma. Gynecol. Oncol. 105(1), 90-96 (2007). (Pubitemid 46441446)
37. Chi DS, Zivanovic O, Levinson KL et al. The incidence of major complications after the performance of extensive upper abdominal surgical procedures during primary cytoreduction of advanced ovarian, tubal, and peritoneal carcinomas. Gynecol. Oncol. 119(1), 38-42 (2010).
38. Gerestein CG, Nieuwenhuyzen-de Boer GM, Eijkemans MJ, Kooi GS, Burger CW. Prediction of 30-day morbidity after primary cytoreductive surgery for advanced stage ovarian cancer. Eur. J. Cancer 46(1), 102-109 (2010).
39. Chi DS, Franklin CC, Levine DA et al. Improved optimal cytoreduction rates for stages IIIC and IV epithelial ovarian, fallopian tube, and primary peritoneal cancer: a change in surgical approach. Gynecol. Oncol. 94(3), 650-654 (2004). (Pubitemid 39194456)
40. Gerestein CG, Damhuis RA, Burger CW, Kooi GS. Postoperative mortality after primary cytoreductive surgery for advanced stage epithelial ovarian cancer: a systematic review. Gynecol. Oncol. 114(3), 523-527 (2009).
41. Harter P, Hilpert F, Mahner S, Kommoss S, Heitz F, du Bois A. Role of cytoreductive surgery in recurrent ovarian cancer. Expert Rev. Anticancer Ther. 9(7), 917-922 (2009).
42. Oksefjell H, Sandstad B, Trope C. The role of secondary cytoreduction in the management of the first relapse in epithelial ovarian cancer. Ann. Oncol. 20(2), 286-293 (2009).
43. Tian WJ, Jiang R, Cheng X, Tang J, Xing Y, Zang RY. Surgery in recurrent epithelial ovarian cancer: benefits on survival for patients with residual disease of 01-1 cm after secondary cytoreduction. J. Surg. Oncol. 101(3), 244-250 (2010).